Login to Download
PDF version

EHOB, Inc Introduces New Foot WAFFLE® Custom and Foot WAFFLE® Heel Elevator Custom

  EHOB, Inc (Indianapolis, IN), released the Foot WAFFLE® Custom and Foot WAFFLE Heel Elevator Custom—the company’s newest lower-extremity products.

  The Foot WAFFLE Custom’s sloped design mirrors the natural shape of the leg as it angles from the calf down to the ankle, securely holding the leg and foot in place. Complete with new, air-filled straps, the product enables pressure ulcer prevention and patient comfort across the top of the leg and foot, while the foot strap and newly modified ankle section prevent shifting of the foot and assistance in the proper alignment of the lower extremity.

  Navigating down the product, the foot-end portion of the Foot WAFFLE Custom features an adjustable, air-filled “pillow pad” that comfortably floats a patient’s foot while also
assisting in the prevention of ankle contractures and the maintenance of normal ankle alignment for patients with foot drop. A Velcro strap located at the end of the product helps accommodate multiple foot widths and clinical applications, and can be adjusted to either float or protect the heel while the product’s wider
opening from the knee to the foot offers increased air circulation.

  The new Foot WAFFLE Custom is recommended for single-patient use, is available in sizes small, medium, and large, and is constructed with nonabrasive, latex-free, medical-grade vinyl.

  Visit www.ehob.com for more information.

Apligraf® Improves Reimbursement for Patients

  Apligraf® (Organogenesis Inc, Canton, MA) has established improved coverage from multiple payors, improving access to care for millions of patients suffering from chronic, nonhealing wounds. This is the only cell-based product with Food and Drug Administration (FDA) approval for the treatment of both diabetic foot ulcers and venous leg ulcers.

  Apligraf is the first bioengineered living cell-based product to have received FDA approval for treatment of diabetic foot ulcers and venous leg ulcers. Clinical studies of the application were based on up to 5 treatments, comprising weekly assessments and/or applications, over a 12-week period.

  Visit www.organogenesis.com for more information.

CE Mark Granted for Patent-based Wound Spray

  Based on a patent by Sangui Biotech International, Inc (Witten, Germany), the technology for a spray aimed at improving the healing of chronic wounds is now available after a certification as Class III medical product was granted. Global licensee SastoMed will be in charge of marketing and distribution of the Granulox product. The CE mark, according to sections 6 and 7 of the Medical Devices Act, authorizes production, distribution, and sales of the product in all member countries of the European Union.

  Visit www.sanguibiotech.com for more information.

DM Systems Report on 2011 Sustainability Improvements at Evanston Headquarters

  DM Systems, Inc (Evanston, IL) released its Environmental Sustainability Report. Focusing on energy efficiency, transportation impacts, waste reduction, and employee engagement, the report demonstrated the difference even small steps can make.

  Working with corporate sustainability consultants Go2Green, the company quickly grasped their current environmental impact, and found areas for improvement. Office improvements for commuting cyclists earned them a bicycle-friendly business designation through the League of American Bicyclists, lighting upgrades reduced carbon dioxide emissions by an estimated 5 tons, and simple changes to printing practices saved cartridges and money.

  Next steps include biodegradable packaging to save their hospital clients the cost of waste disposal.